Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 6Phase 1 4Phase 3 3Phase 4 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 18Prostatic Neoplasms 16Breast Neoplasms 11Recurrence 8Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Colorectal Neoplasms 6Ovarian Neoplasms 5Myelodysplastic Syndromes 5Multiple Myeloma 5Melanoma 5Leukemia 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Fatigue 4Vomiting 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms, Castration-Resistant 3Pain 3Oropharyngeal Neoplasms 3Nausea 3Mesothelioma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Liposarcoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

fludarabine 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Leukemia, B-Cell × Clear all
NCT00714259 2017-07-24

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

University of Alabama at Birmingham

Phase 2/3 Terminated
5 enrolled 11 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡